Rapport Therapeutics RAPP
NASDAQ RAPP
$25.06 -4.31 (-14.67%)
At close: Oct 21, 2026 · 4:00 PM EDT

Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024)

Updated

Rapport Therapeutics (RAPP) posted Preferred Stock Liabilities of $234.74 million for Q1 2024, up 40.9% from the prior quarter.

Analysis

Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends

At the end of FY2023, Rapport Therapeutics' Preferred Stock Liabilities came in at $166.58 million.

  • According to Business Quant data, Preferred Stock Liabilities for the three prior quarters was $166.58 million (Q4 2023), $166.58 million (Q3 2023) and $89.49 million (Q2 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Rapport Therapeutics 1.19 Bn 367.93 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 234.74 Mn
Dec 31, 2023 166.58 Mn
Sep 30, 2023 166.58 Mn
Jun 30, 2023 89.49 Mn
API Access

Rapport Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=RAPP&period=max&api_key=YOUR_API_KEY